MedTrace Logo

Efficacy and Safety of BG2109 During Controlled Ovarian Hyperstimulation in Female Subjects Undergoing ART Procedures

NCT05738382 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2023-07-27

No results posted yet for this study

Summary

To explore the optimal effective daily dose of BG2109 to suppress premature luteinizing hormone (LH) surge during COH in female subjects undergoing ART procedures.

Conditions

  • Assisted Reproductive Technology
  • Controlled Ovarian Hyperstimulation

Interventions

DRUG

BG2109

oral administration once daily

DRUG

Cetrorelix

0.25 mg, Subcutaneous injection once daily.

Sponsors & Collaborators

  • Bio Genuine (Shanghai) Biotech Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Xiaoyan Liang · Sixth Affiliated Hospital, Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
39 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-31
Primary Completion
2024-06-30
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05738382 on ClinicalTrials.gov